APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic SGLT-2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antidiabetic SGLT-2 Inhibitor Market Outlook and Growth Opportunities 2026

20 December 2025194 pages

Choose your research edition.

Industry ResearchAntidiabetic SGLT-2 Inhibitor Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic SGLT-2 Inhibitor Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Antidiabetic SGLT-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic SGLT-2 Inhibitor Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic SGLT-2 Inhibitor Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Antidiabetic SGLT-2 Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antidiabetic SGLT-2 Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antidiabetic SGLT-2 Inhibitor market include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic SGLT-2 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic SGLT-2 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic SGLT-2 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic SGLT-2 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic SGLT-2 Inhibitor Segment by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Novo Nordisk

Servier Laboratories

AstraZeneca

GlaxoSmithKline

Pfizer

Eli Lilly

Merck & Co

Johnson & Johnson

Sanofi

Takeda Pharmaceuticals

Antidiabetic SGLT-2 Inhibitor Segment by Type

Canagliflozin

Dapagliflozin

Empagliflozin

Other

Antidiabetic SGLT-2 Inhibitor Segment by Application

Hospitals

Clinics

Other

Antidiabetic SGLT-2 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antidiabetic SGLT-2 Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antidiabetic SGLT-2 Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antidiabetic SGLT-2 Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Antidiabetic SGLT-2 Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic SGLT-2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic SGLT-2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic SGLT-2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic SGLT-2 Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antidiabetic SGLT-2 Inhibitor industry.

Chapter 3: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antidiabetic SGLT-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antidiabetic SGLT-2 Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic SGLT-2 Inhibitor Industry Trends Table 2. Antidiabetic SGLT-2 Inhibitor Industry Drivers Table 3. Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges Table 4. Antidiabetic SGLT-2 Inhibitor Industry Restraints Table 5. Global Antidiabetic SGLT-2 Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global Antidiabetic SGLT-2 Inhibitor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antidiabetic SGLT-2 Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antidiabetic SGLT-2 Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global Antidiabetic SGLT-2 Inhibitor Company, Product Type & Application Table 13. Global Antidiabetic SGLT-2 Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Canagliflozin Table 18. Significant Companies of Dapagliflozin Table 19. Significant Companies of Empagliflozin Table 20. Significant Companies of Other Table 21. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Type (2021-2026) Table 25. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Type (2027-2032) Table 26. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type (2021-2026) Table 30. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Clinics Table 33. Significant Companies of Other Table 34. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Application (2021-2026) Table 38. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Application (2027-2032) Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application (2021-2026) Table 43. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application (2027-2032) Table 44. Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 46. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2021-2026) Table 47. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2027-2032) & (K Units) Table 48. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2027-2032) Table 49. Global Antidiabetic SGLT-2 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Region (2021-2026) Table 52. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Region (2027-2032) Table 54. Global Antidiabetic SGLT-2 Inhibitor Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Antidiabetic SGLT-2 Inhibitor Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Antidiabetic SGLT-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 59. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2021-2026) Table 60. Global Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 61. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2027-2032) Table 62. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Antidiabetic SGLT-2 Inhibitor Sales Value Market Share by Country (2021-2026) Table 64. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Antidiabetic SGLT-2 Inhibitor Sales Value Market Share by Country (2027-2032) Table 66. Boehringer Ingelheim Company Information Table 67. Boehringer Ingelheim Business Overview Table 68. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 70. Boehringer Ingelheim Recent Development Table 71. Bristol-Myers Squibb Company Information Table 72. Bristol-Myers Squibb Business Overview Table 73. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 75. Bristol-Myers Squibb Recent Development Table 76. Novo Nordisk Company Information Table 77. Novo Nordisk Business Overview Table 78. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 80. Novo Nordisk Recent Development Table 81. Servier Laboratories Company Information Table 82. Servier Laboratories Business Overview Table 83. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 85. Servier Laboratories Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 90. AstraZeneca Recent Development Table 91. GlaxoSmithKline Company Information Table 92. GlaxoSmithKline Business Overview Table 93. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 95. GlaxoSmithKline Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 100. Pfizer Recent Development Table 101. Eli Lilly Company Information Table 102. Eli Lilly Business Overview Table 103. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 105. Eli Lilly Recent Development Table 106. Merck & Co Company Information Table 107. Merck & Co Business Overview Table 108. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 110. Merck & Co Recent Development Table 111. Johnson & Johnson Company Information Table 112. Johnson & Johnson Business Overview Table 113. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 115. Johnson & Johnson Recent Development Table 116. Sanofi Company Information Table 117. Sanofi Business Overview Table 118. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 120. Sanofi Recent Development Table 121. Takeda Pharmaceuticals Company Information Table 122. Takeda Pharmaceuticals Business Overview Table 123. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 125. Takeda Pharmaceuticals Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Antidiabetic SGLT-2 Inhibitor Distributors List Table 129. Antidiabetic SGLT-2 Inhibitor Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Antidiabetic SGLT-2 Inhibitor Product Image Figure 2. Global Antidiabetic SGLT-2 Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic SGLT-2 Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic SGLT-2 Inhibitor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antidiabetic SGLT-2 Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Canagliflozin Image Figure 10. Dapagliflozin Image Figure 11. Empagliflozin Image Figure 12. Other Image Figure 13. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Type (2021-2032) Figure 16. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Other Image Figure 22. Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Application (2021-2032) Figure 25. Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application (2021-2032) Figure 28. Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Antidiabetic SGLT-2 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 33. North America Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 39. South America Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Antidiabetic SGLT-2 Inhibitor Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Antidiabetic SGLT-2 Inhibitor Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novo Nordisk
  • Servier Laboratories
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck & Co
  • Johnson & Johnson
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antidiabetic SGLT-2 Inhibitor Market Dynamics
  1. 2.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
  2. 2.2 Antidiabetic SGLT-2 Inhibitor Industry Drivers
  3. 2.3 Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 Antidiabetic SGLT-2 Inhibitor Industry Restraints
3 Antidiabetic SGLT-2 Inhibitor Market by Company
  1. 3.1 Global Antidiabetic SGLT-2 Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global Antidiabetic SGLT-2 Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global Antidiabetic SGLT-2 Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global Antidiabetic SGLT-2 Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global Antidiabetic SGLT-2 Inhibitor Company Product Type and Application
  8. 3.8 Global Antidiabetic SGLT-2 Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antidiabetic SGLT-2 Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antidiabetic SGLT-2 Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antidiabetic SGLT-2 Inhibitor Market by Type
  1. 4.1 Antidiabetic SGLT-2 Inhibitor Type Introduction
  2. 4.1.1 Canagliflozin
  3. 4.1.2 Dapagliflozin
  4. 4.1.3 Empagliflozin
  5. 4.1.4 Other
  6. 4.2 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type
  7. 4.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type
  11. 4.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Type (2021-2032)
  13. 4.3.3 Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type (2021-2032)
5 Antidiabetic SGLT-2 Inhibitor Market by Application
  1. 5.1 Antidiabetic SGLT-2 Inhibitor Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application
  6. 5.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application
  10. 5.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Application (2021-2032)
  12. 5.3.3 Global Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application (2021-2032)
6 Antidiabetic SGLT-2 Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global Antidiabetic SGLT-2 Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Antidiabetic SGLT-2 Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antidiabetic SGLT-2 Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antidiabetic SGLT-2 Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antidiabetic SGLT-2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antidiabetic SGLT-2 Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Servier Laboratories
  20. 8.4.1 Servier Laboratories Company Information
  21. 8.4.2 Servier Laboratories Business Overview
  22. 8.4.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio
  24. 8.4.5 Servier Laboratories Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Merck & Co
  50. 8.9.1 Merck & Co Company Information
  51. 8.9.2 Merck & Co Business Overview
  52. 8.9.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio
  54. 8.9.5 Merck & Co Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
  61. 8.11 Sanofi
  62. 8.11.1 Sanofi Company Information
  63. 8.11.2 Sanofi Business Overview
  64. 8.11.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio
  66. 8.11.5 Sanofi Recent Developments
  67. 8.12 Takeda Pharmaceuticals
  68. 8.12.1 Takeda Pharmaceuticals Company Information
  69. 8.12.2 Takeda Pharmaceuticals Business Overview
  70. 8.12.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio
  72. 8.12.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic SGLT-2 Inhibitor Value Chain Analysis
  2. 9.1.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic SGLT-2 Inhibitor Sales Mode & Process
  6. 9.2 Antidiabetic SGLT-2 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic SGLT-2 Inhibitor Distributors
  9. 9.2.3 Antidiabetic SGLT-2 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst